openPR Logo
Press release

Antiprotozoal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

05-18-2020 04:25 PM CET | Health & Medicine

Press release from: Transparency Market Research

Protozoa are unicellular, non-phototrophic, eukaryotic microorganisms lacking cell walls. This group comprises over 65,000 species. Most protozoa cause a number of diseases in animals and humans. In the cyst stage of the life cycle, protozoa are most dormant and resistant to environmental stress factors. Cysts are often the mode of infection in disease causing protozoa. These infectious agents are usually transmitted through fecal-oral route. The major disease-causing protozoans include Plasmodium spp., Trypanosoma spp., and Leishmania spp. Diseases caused by these protozoans lead to significant mortality, morbidity, and economy losses in developing countries. Protozoal infections arise due to poor sanitary conditions, improper hygiene, and lack of vector control methods in tropical and sub-tropical countries. Antiprotozoal drugs are therefore used to combat these diseases. Antiprotozoal drugs kill or inhibit the reproductive ability of a protozoa, preventing further infections.

Major diseases caused by protozoa include amebiasis, malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, and giardiasis. Amebiasis is a gastrointestinal tract disease, caused by Entamoeba histolytica, which is an anaerobic parasitic protozoan. 50 million people worldwide are infected with Entamoeba histolytica. Diarrhea and dysentery are the most common signs and symptoms of this infection. Malaria is transmitted through the bite of a female Anopheles mosquito. Patients show symptoms of fever and chills. Plasmodium falciparum, vivax, malariae, and ovale are the causative agents of malaria. The disease is endemic in various countries.

Request Sample Of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30497

Leishmaniasis, trypanosomiasis, toxoplasmosis, and giardiasis are the most common protozoan infections leading to a number of deaths worldwide. Demand for antiprotozoal drugs is high as there are no vaccines available for the treatment of these diseases and therapy depends on antiprotozoal drugs. Increasing demand for new antiprotozoal drugs, owing to the problems such as poor efficacy, unsuitable pharmacokinetic properties, and drug resistance of preexisting drugs. Moreover, rising population, poverty, poor hygiene, sanitary conditions in underdeveloped and developing countries, and increasing awareness about these diseases are the major drivers of the antiprotozoal drugs market. However, high cost and inadequate pharmaceutical research restrain the market.

In terms of causative agent, the antiprotozoal drugs market has been segmented into antimalarial drugs, amebicides, trichomonacides, antigiardial, leishmaniacides, trypanocides, and toxoplasmocides. Amebicides comprise antiprotozoal agents such as arsenicals, quinoline derivatives, and drugs from natural source, emetine, hydroxyquinolone, diloxanide furate, paramomycin3, carbarsone, nitroimidazole derivatives, and chloroquine. Anti-malarial drugs consists of 8-aminoqinoline, cinchona alkaloids, 4-amino quinines, 9-acridine, sulfone, and biguanides. Trichomonacides comprise metronidazole. Antigiardial consists of metronidazole. Leishmaniacides consists of sodium stibogluconate and pentamidine. Trypanocides class of drugs comprise suramin and pentamidine, while toxoplasmocides consist of pyrimethamine along with sulfadiazine. The antiprotozoal drugs market has also been segmented based on mode of action and type of treatment. In terms of end-user, the antiprotozoal drugs market has been segmented into hospitals, private clinics, pharmacies, non-governmental organizations, research institutes, and e-commerce. The pipeline for new antiprotozoal drugs is projected to boost the growth of the global antiprotozoal drugs market.

Request the Coronavirus Impact Analysis on this Markets - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=30497

Based on region, the global antiprotozoal drugs market has been segmented into North America, Latin America, Asia Pacific, Africa, Western Europe, and Eastern Europe. However, the market is divided according to the type of infection and its prevalence in each region. For instance, the global market for antimalarial, leishmaniacides, and amebicide drugs is concentrated in developing countries in Asia Pacific and Africa. Rapid research & development activities by pharmaceutical companies can lead to introduction of new scientific technology, methods, and treatments to cure these diseases. This, in turn, is anticipated to drive demand for antiprotozoal infection drugs during the forecast period.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30497

Key players in the global antiprotozoal drugs market include Enzon Pharmaceuticals (Abelcet), Paladin Therapeutics, Inc., Sequus Pharmaceuticals, Lifecare Innovation, Sanofi, Pfizer, Inc., Ranbaxy Laboratories, GlaxoSmithKline plc, Novartis AG, Ipca Laboratories Ltd., Merck KGaA, and F. Hoffmann La-Roche Ltd.

More Trending Reports by Transparency Market Research - https://www.biospace.com/article/ventilator-accessories-market-geographical-outlook-and-competitive-landscape/

Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antiprotozoal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 here

News-ID: 2049454 • Views:

More Releases from Transparency Market Research

Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / By Function | Europe • North America • Asia Pacific
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / …
The global functional coffee market was valued at US$ 21.5 Bn in 2024 and is projected to reach US$ 48.1 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2035. This steady growth trajectory reflects the strong convergence of coffee consumption habits with rising demand for functional and wellness-oriented beverages. Functional coffee has transitioned from a niche category to a mainstream product offering,
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reach USD 23.6 Billion by 2036 | Transparency Market Research
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reac …
The global electric face cleanser market is witnessing a transformative growth phase as consumers increasingly integrate advanced skincare technologies into their daily routines. Valued at USD 9.8 billion in 2025, the market is projected to expand significantly and reach USD 23.6 billion by 2036, growing at a healthy compound annual growth rate (CAGR) of 8.6% from 2026 to 2036. This growth trajectory underscores the rising importance of personal care technology,
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% CAGR Driven by Rising Respiratory Disease Burden
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% …
The global asthma and COPD drugs market demonstrated strong fundamentals in 2025, with a valuation of US$ 44.7 Bn, reflecting the essential and recurring nature of respiratory therapeutics. Supported by a growing patient base and continuous pharmaceutical innovation, the market is projected to reach US$ 82.2 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2036. This growth trajectory highlights the increasing reliance on
Low-Alcohol Beverages Market Outlook 2035: Global Industry Set to Expand from US$ 2.1 Bn to US$ 4.6 Bn by 2035 at 7.5% CAGR
Low-Alcohol Beverages Market Outlook 2035: Global Industry Set to Expand from US …
The global low-alcohol beverages market is undergoing a structural transformation as consumers increasingly prioritize health, moderation, and mindful drinking without sacrificing taste or social experiences. Valued at US$ 2.1 billion in 2024, the market is projected to reach US$ 4.6 billion by 2035, expanding at a healthy CAGR of 7.5% from 2025 to 2035. This sustained growth reflects changing lifestyle preferences, generational shifts in alcohol consumption, and continuous innovation by

All 5 Releases


More Releases for Leishmania

Leishmaniasis Pipeline Insight 2025: Emerging Drugs, Novel Antiparasitic Approac …
DelveInsight's "Leishmaniasis - Pipeline Insight, 2025" highlights over 3+ drugs in development for leishmaniasis, a neglected tropical disease caused by Leishmania parasites and transmitted through sandfly bites. Despite being endemic in more than 90 countries, treatment options remain limited, with toxicity, resistance, and access issues affecting the leishmaniasis treatment market. The growing research focus on safer, more effective, and affordable therapies underscores the urgent unmet needs in endemic regions. The leishmaniasis
Leishmaniasis - Pipeline Insight, 2025: Advancing Antiparasitic Innovation Amids …
Leishmaniasis, a neglected tropical disease caused by protozoan parasites of the genus Leishmania, remains a serious global health concern, especially in endemic regions across Asia, Africa, South America, and the Middle East. With high morbidity, limited treatment options, and growing resistance to traditional therapies like pentavalent antimonials, the need for novel, effective, and safer therapies has become more urgent than ever. DelveInsight's "Leishmaniasis - Pipeline Insight, 2025" profiles more than 3+
The Role of Novel Antibodies in Infectious Disease Control
The control of infectious diseases has been revolutionized by the development of novel antibodies. These innovative molecules are designed to specifically target pathogens, offering a more precise and effective approach to treatment and prevention. Novel antibodies have shown promise in combating a wide range of infectious agents, including bacteria, viruses, and parasites, by neutralizing pathogens, enhancing immune responses, and preventing infections. Download Multispecific & Cancer Combination Report: https://www.kuickresearch.com/ccformF.php?t=1722618060 One of the key applications
Paromomycin Sulfate Market 2030 by Top 10+ Players Pfizer,, Changrui Pharm,, ERF …
Paromomycin Sulfate is an antibiotic used to treat infections caused by certain parasites. It is commonly used to treat visceral leishmaniasis, a serious parasitic disease that affects the internal organs. The market for Paromomycin Sulfate is relatively small compared to other antibiotics, as it is primarily used to treat a specific type of parasitic infection. However, the market for Paromomycin Sulfate is expected to grow as the incidence of visceral
Leishmaniasis Treatment Market Outlook 2021-2027- Sales Revenue, Industry Growt …
The global market for leishmaniasis therapy can be divided into three categories: drug type, diagnostic method, and vector control method. Leishmaniasis is a parasitic disease caused by Leishmania. The Leishmania parasite is a single-celled protozoan that is spread through the bite of an infected female phlebotomine sand fly. Use of nets or mesh, sprays, and pesticides effective against sandflies are all examples of market segmentation by vector control strategies. Leishmaniasis Treatment
Leishmaniasis Treatment Market Expected to Raise at CAGR of 8.8% by 2019-2026 | …
According to the current analysis of Reports and Data, the global Leishmaniasis Treatment market was valued at USD 104.8 million in 2018 and is expected to reach USD 206.5 million by the year 2026, at a CAGR of 8.8%. A disease outbreak takes place when a disease escalates by a higher number than expected in a region or during a season. An outbreak may occur in one community or even